{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:24:51Z","timestamp":1763389491600,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013048","name":"Fundamental and Frontier Research Project of Chongqing","doi-asserted-by":"publisher","award":["project no. cstc2018jsyj-jsyjX0015"],"award-info":[{"award-number":["project no. cstc2018jsyj-jsyjX0015"]}],"id":[{"id":"10.13039\/501100013048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mature B cell acute lymphoblastic leukaemia (BAL) is characterised by French\u2013American\u2013British (FAB)-L3 morphology and the presence of surface immunoglobulin (sIgM) light chain restriction. BAL is also considered as the leukaemic phase of Burkitt lymphoma (BL), in which t (8; 14) (q24; q32) or its variants are related to the myelocytomatosis oncogene (MYC) rearrangement (MYCr) is usually present. However, BAL with lysine methyltransferase 2A (KMT2A, previously called Mixed lineage leukaemia, MLL) gene rearrangement (KMT2Ar, previously called MLLr) is rare.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three BAL patients with KMT2Ar were enrolled between January 2017 and November 2019, accounting for 1.37% of the B-ALL population in our hospital. We also reviewed 24 previously reported cases of BAL and KMT2Ar and analysed the features, treatment, and prognosis. Total 13 males and 14 females were enrolled in our research, and the average age at diagnosis was 19.5\u2009\u00b1\u20094.95\u00a0months old. In these 27 patients, renal, central nervous system (CNS) and skin involvement were existent in 6, 4 and 3 patients, respectively; 26 patients (26\/27) showed non-ALL-L3 morphology, while one patient is ALL-L3; overexpression of CD19 was detected in most cases, negative or suspicious expression of CD20 was found in 64% of patients. KMT2Ar was reported, but MYCr was not observed. 25 patients (25\/27) achieved complete remission after chemotherapy or Stem cell transplantation. The patients were sensitive to chemotherapy, prospective event-free survival (pEFS) of BAL patients with KMT2Ar who received allogeneic haematopoietic stem cell transplantation (allo-HSCT) was higher than that in patients who received chemotherapy alone (83.33% vs 41.91%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>BAL patients with KMT2Ar had unique manifestations, including younger age at diagnosis and overexpression of CD19; expression of CD20 was rare, and MYCr was undetectable. The pEFS was higher in patients undergoing allo-HSCT than in patients undergoing chemotherapy alone.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01972-5","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T14:02:44Z","timestamp":1627653764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mature B cell acute lymphoblastic leukaemia with KMT2A-MLLT3 transcripts in children: three case reports and literature reviews"],"prefix":"10.1186","volume":"16","author":[{"given":"Yinghui","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinli","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9286","authenticated-orcid":false,"given":"Jianwen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"1972_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/ajh.25124","volume":"93","author":"L Cui","year":"2018","unstructured":"Cui L, Li Z-G, Chai Y-H, Yu J, Gao J, Zhu X-F, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: the first nation-wide prospective multicenter study in China. Am J Hematol. 2018;93:913\u201320. https:\/\/doi.org\/10.1002\/ajh.25124.","journal-title":"Am J Hematol"},{"key":"1972_CR2","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer (IARC) 69372 Lyon Cedex 08, France; 2017."},{"key":"1972_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11899-018-0456-8","volume":"13","author":"C Wenzinger","year":"2018","unstructured":"Wenzinger C, Williams E, Gru AA. Updates in the pathology of precursor lymphoid neoplasms in the revised fourth edition of the WHO classification of tumors of hematopoietic and lymphoid tissues. Curr Hematol Malig Rep. 2018;13:275\u201388. https:\/\/doi.org\/10.1007\/s11899-018-0456-8.","journal-title":"Curr Hematol Malig Rep"},{"key":"1972_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.leukres.2014.11.017","volume":"39","author":"T Burmeister","year":"2015","unstructured":"Burmeister T, Meyer C, Gr\u00f6ger D, Hofmann J, Marschalek R. Evidence-based RT-PCR methods for the detection of the 8 most common MLL aberrations in acute leukemias. Leuk Res. 2015;39:242\u20137. https:\/\/doi.org\/10.1016\/j.leukres.2014.11.017.","journal-title":"Leuk Res"},{"key":"1972_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27266","volume":"65","author":"L Yang","year":"2018","unstructured":"Yang L, Ding L, Liang J, Chen J, Tang Y, Xue H, et al. Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations. Pediatr Blood Cancer. 2018;65: e27266. https:\/\/doi.org\/10.1002\/pbc.27266.","journal-title":"Pediatr Blood Cancer"},{"key":"1972_CR6","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","volume":"124","author":"D Hoelzer","year":"2014","unstructured":"Hoelzer D, Walewski J, D\u00f6hner H, Viardot A, Hiddemann W, Spiekermann K, et al. Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124:3870\u20139.","journal-title":"Blood"},{"key":"1972_CR7","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3109\/10428194.2015.1085529","volume":"57","author":"JY Song","year":"2016","unstructured":"Song JY, Venkataraman G, Fedoriw Y, Herrera AF, Siddiqi T, Alikhan MB, et al. Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults. Leuk Lymphoma. 2016;57:866\u201371. https:\/\/doi.org\/10.3109\/10428194.2015.1085529.","journal-title":"Leuk Lymphoma"},{"key":"1972_CR8","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3109\/10428194.2016.1141407","volume":"57","author":"EO Sajaroff","year":"2016","unstructured":"Sajaroff EO, Mansini A, Rubio P, Alonso CN, Gallego MS, Cocc\u00e9 MC, et al. B-cell acute lymphoblastic leukemia with mature phenotype and MLL rearrangement: report of five new cases and review of the literature. Leuk Lymphoma. 2016;57:2289\u201397. https:\/\/doi.org\/10.3109\/10428194.2016.1141407.","journal-title":"Leuk Lymphoma"},{"key":"1972_CR9","first-page":"947","volume":"39","author":"QH Yao","year":"2018","unstructured":"Yao QH, Liu YF, Fang YQ, Zhao XM. [Childhood B-cell acute lymphoblastic leukemia of nonL3 morphology with mature phenotype and MLL-AF9 gene fusion: a case report and literatures review]. Zhonghua Xue Ye Xue Za Zhi. 2018;39:947\u20139.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"1972_CR10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1182\/blood.V92.2.574","volume":"92","author":"N Pallisgaard","year":"1998","unstructured":"Pallisgaard N, Hokland P, Riish\u00f8j DC, Pedersen B, J\u00f8rgensen P. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood. 1998;92:574\u201388.","journal-title":"Blood"},{"key":"1972_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1309\/LM0BOC84GSQGHYKD","volume":"46","author":"MC Smith","year":"2015","unstructured":"Smith MC, Kressin MK, Crawford E, Wang XJ, Kim AS. B Lymphoblastic leukemia with a novel t(11;15) (q23;q15) and unique Burkittoid morphologic and immunophenotypic findings in a 9-year-old boy. Lab Med. 2015;46:320\u20136. https:\/\/doi.org\/10.1309\/LM0BOC84GSQGHYKD.","journal-title":"Lab Med"},{"key":"1972_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12185-016-1971-9","volume":"104","author":"T Sarashina","year":"2016","unstructured":"Sarashina T, Iwabuchi H, Miyagawa N, Sekimizu M, Yokosuka T, Fukuda K, et al. Hematopoietic stem cell transplantation for pediatric mature B-cell acute lymphoblastic leukemia with non-L3 morphology and MLL-AF9 gene fusion: three case reports and review of the literature. Int J Hematol. 2016;104:139\u201343. https:\/\/doi.org\/10.1007\/s12185-016-1971-9.","journal-title":"Int J Hematol"},{"key":"1972_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/gcc.2870030113","volume":"3","author":"AN Lorenzana","year":"1991","unstructured":"Lorenzana AN, Rubin CM, Le Beau MM, Nachman J, Connolly P, Subramanian U, et al. Immunoglobulin gene rearrangements in acute lymphoblastic leukemia with the 9;11 translocation. Genes Chromosom Cancer. 1991;3:74\u20137. https:\/\/doi.org\/10.1002\/gcc.2870030113.","journal-title":"Genes Chromosom Cancer"},{"key":"1972_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00282-996-0265-8","volume":"38","author":"P Talmant","year":"1996","unstructured":"Talmant P, Berger R, Robillard N, Mechineau-Lacroix F, Garand R. Childhood B-cell acute lymphoblastic leukemia with FAB-L1 morphology and a t(9;11) translocation involving the MLL gene. Hematol Cell Ther. 1996;38:265\u20138. https:\/\/doi.org\/10.1007\/s00282-996-0265-8.","journal-title":"Hematol Cell Ther"},{"key":"1972_CR15","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.5858\/2003-127-1340-IBALLW","volume":"127","author":"S Li","year":"2003","unstructured":"Li S, Lew G. Is B-lineage acute lymphoblastic leukemia with a mature phenotype and l1 morphology a precursor B-lymphoblastic leukemia\/lymphoma or Burkitt leukemia\/lymphoma? Arch Pathol Lab Med. 2003;127:1340\u20134.","journal-title":"Arch Pathol Lab Med"},{"key":"1972_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/modpathol.3800128","volume":"17","author":"L Tsao","year":"2004","unstructured":"Tsao L, Draoua HY, Osunkwo I, Nandula SV, Murty VVS, Mansukhani M, et al. Mature B-cell acute lymphoblastic leukemia with t(9;11) translocation: a distinct subset of B-cell acute lymphoblastic leukemia. Mod Pathol. 2004;17:832\u20139.","journal-title":"Mod Pathol"},{"key":"1972_CR17","doi-asserted-by":"publisher","unstructured":"Frater JL, Batanian JR, O'Connor DM, Grosso LE. Lymphoblastic Leukemia With Mature B-Cell Phenotype in Infancy. J Pediatr Hematol Oncol. 2004 Oct;26(10):672\u20137. https:\/\/doi.org\/10.1097\/01.mph.0000142493.56793.","DOI":"10.1097\/01.mph.0000142493.56793"},{"key":"1972_CR18","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/sj.leu.2404992","volume":"22","author":"N Blin","year":"2008","unstructured":"Blin N, M\u00e9chinaud F, Talmant P, Garand R, Boutard P, Dastugue N, et al. Mature B-cell lymphoblastic leukemia with MLL rearrangement: an uncommon and distinct subset of childhood acute leukemia. Leukemia. 2008;22:1056\u20139.","journal-title":"Leukemia"},{"key":"1972_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1365-2141.2012.09091.x","volume":"157","author":"L Lim","year":"2012","unstructured":"Lim L, Chen K-S, Krishnan S, Gole L, Ariffin H. Mature B-cell acute lymphoblastic leukaemia associated with a rare MLL-FOXO4 fusion gene. Br J Haematol. 2012;157:651\u2013651. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09091.x.","journal-title":"Br J Haematol"},{"key":"1972_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3343\/alm.2014.34.2.166","volume":"34","author":"B Kim","year":"2014","unstructured":"Kim B, Lee S-T, Kim H-J, Lee S-H, HeeYoo K, Koo HH, et al. Acute lymphoblastic leukemia with mature B-cell phenotype and t(9;11;11)(p22;q23;p11.2): a case study and literature review. Ann Lab Med. 2014;34:166\u20139. https:\/\/doi.org\/10.3343\/alm.2014.34.2.166.","journal-title":"Ann Lab Med"},{"key":"1972_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","volume":"370","author":"R Pieters","year":"2007","unstructured":"Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370:240\u201350.","journal-title":"Lancet"},{"key":"1972_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3109\/08880018.2013.783891","volume":"30","author":"J Worch","year":"2013","unstructured":"Worch J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents\u2014review of standard chemotherapy regimen and perspectives. Pediatr Hematol Oncol. 2013;30:465\u201383. https:\/\/doi.org\/10.3109\/08880018.2013.783891.","journal-title":"Pediatr Hematol Oncol"},{"key":"1972_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1309\/WTXCQ5NRACVXTYBY","volume":"121","author":"R Kansal","year":"2004","unstructured":"Kansal R, Deeb G, Barcos M, Wetzler M, Brecher ML, Block AW, et al. Precursor B lymphoblastic leukemia with surface light chain immunoglobulin restriction. Am J Clin Pathol. 2004;121:512\u201325. https:\/\/doi.org\/10.1309\/WTXCQ5NRACVXTYBY.","journal-title":"Am J Clin Pathol"},{"key":"1972_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2407-13-55","volume":"13","author":"VY Chang","year":"2013","unstructured":"Chang VY, Basso G, Sakamoto KM, Nelson SF. Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia. BMC Cancer. 2013;13:55. https:\/\/doi.org\/10.1186\/1471-2407-13-55.","journal-title":"BMC Cancer"},{"key":"1972_CR25","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","volume":"14","author":"I Magrath","year":"1996","unstructured":"Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925\u201334. https:\/\/doi.org\/10.1200\/JCO.1996.14.3.925.","journal-title":"J Clin Oncol"},{"key":"1972_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","volume":"34","author":"JS Abramson","year":"2020","unstructured":"Abramson JS. Anti-CD19 CAR T-cell therapy for B-cell non-hodgkin lymphoma. Transfus Med Rev. 2020;34:29\u201333. https:\/\/doi.org\/10.1016\/j.tmrv.2019.08.003.","journal-title":"Transfus Med Rev"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01972-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01972-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01972-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T14:05:21Z","timestamp":1627653921000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01972-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1972"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01972-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"21 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved on 22 April 2015 by the institutional ethics committee (Institutional Review Board of Children\u2019s Hospital of Chongqing Medical University). The study was registered the 4 June 2014 and the 22 May 2018 under the Chinese Clinical Trial Registry identifier ChiCTR-IPR-14005706 and ChiCTR1900025690( & ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients in this manuscript have given written informed consent to the publication of their case details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"331"}}